Ranolazine (piperazine acetamide) is a partial fatty acid oxidation (pFOX) inhibitor and represents a new class of metabolic inhibitors for the treatment of chronic stable angina (CSA). The compound was originally developed by Syntex, which was acquired by Roche in October 1994, and became a subsidiary (Syntex (USA)) of Roche Bioscience in 1995.